Shire CEO Sees Opportunity In Vyvanse, Rare Diseases Wall Street Journal LN) Vyvanse, a drug for attention deficit hyperactivity disorder, may help its position in an increasingly competitive market, according to Chief Executive ... and more » |
 RTT News | Newer Products Balance Adderall Generics in Shire's 1Q Morningstar.com We should also see data applying Vyvanse's abuse-resistant technology to Intuniv in the second half of the year, which could be particularly important for ... Shire Q1 beats forecasts, repeats growth target Reuters Shire lifted by American take-up of ADHD drug Times Online Shire beats forecasts as new drugs plug gap left by generic competition Telegraph.co.uk PR Newswire (press release) - Financial Times - Wall Street Journal all 46 news articles » |
New drugs fill the gap at Shire Financial Times Some of the fastest growing drugs at Shire are Vyvanse, another attention deficit disorder drug, where sales rose 32 per cent compared with the first three ... Shire Q1 beats forecasts, repeats growth target Reuters Shire's Replenished Portfolio Drives Excellent Quarterly Performance PR Newswire (press release) Shire Beats Views As Replagal Unseats Genzyme In EU Wall Street Journal Pharma Times - ShareCast all 39 news articles » |
RTT News | Shire Q1 beats forecasts, repeats growth target Reuters Shire has bolstered its hyperactivity franchise with new drugs Vyvanse and Intuniv, as Adderall XR wanes in the face of generic competition from Israel's ... Shire lifted by American take-up of ADHD drug Times Online Shire beats forecasts as new drugs plug gap left by generic competition Telegraph.co.uk New drugs fill the gap at Shire Financial Times Wall Street Journal - Pharma Times - ShareCast all 46 news articles » |
Mind Games Wall Street Journal As counterintuitive as it may seem to give stimulants to people who can't sit down, drugs such as Ritalin, Adderall, Concerta and Vyvanse increase ... |